Summary
Sepsis is characterized by a concurrent activation of inflammation and coagulation.
Recently, recombinant human activated protein C was shown to decrease mortality in
patients with severe sepsis presumably due to a combined anti-inflammatory and anticoagulant
effect.These promising findings led to a search for other products that influence
both the inflammatory and the procoagulant response to severe infection. Ethyl pyruvate
(EP) was recently identified as an experimental anti-inflammatory agent during endotoxemia
and sepsis. The aim of the present study was to investigate whether EP influences
coagulation besides its anti-inflammatory effects. For this we investigated the effects
of EP on the expression and function of tissue factor (TF), the principal initiator
of coagulation activation in sepsis, in human monocytic (THP-1) cell cultures. EP
dose-dependently inhibited the production of tumor necrosis factor (TNF)-α, macrophage
inflammatory protein (MIP)-1α and MIP-1β by lipopolysaccharide (LPS)-stimulated THP-1
cells at mRNA and protein level, thereby confirming its anti-inflammatory properties
in this in-vitro system.In addition, EP dose-dependently attenuated the increases
in TF mRNA levels,TF-protein-surface expression and cell-surface-associated TF activity
in LPS-stimulated THP-1 cells. These results demonstrate for the first time that EP
is a compound with combined anti-inflammatory and anticoagulant effects.
Keywords
Tissue factor - ethyl pyruvate - sepsis - lipopolysaccharide - THP-1 monocytic cells